Beck named new Iridex CEO

October 19, 2011

Dominik Beck, PhD, has been named president and chief executive officer (CEO) of Iridex Corp.

Mountain View, CA-Dominik Beck, PhD, has been named president and chief executive officer (CEO) of Iridex Corp.

In this role, he succeeds company co-founder Theodore A. Boutacoff, who will become chief technology officer. Dr. Beck also will replace Boutacoff on the company’s board of directors.

Before joining Iridex, Dr. Beck was president and chief operating officer (COO) of Haag-Streit U.S. Holdings, a subsidiary of Switzerland-based Haag-Streit International, roles he held since 2003. Prior to working for Haag-Streit, Dr. Beck was CEO of Ophthalmic Development Co. of Switzerland. His career also included a stint as COO of the medical division of Swiss company Volpi AG.

“Dominik has demonstrated that he has the commercial vision and business acumen to accelerate Iridex along its strategic path of growth and profitability,” said William M. Moore, Iridex chairman. “He has exceptional leadership skills and a breadth of background in our business segment, both nationally and internationally, that will allow him to contribute immediately to our organization and accelerate our synergistic strategy of diagnostic and therapeutic platforms. Under Dominik’s leadership, we believe we are well-positioned to execute commercially and to meet a growing number of strategic and clinical milestones.”

Dr. Beck said, “We have a number of innovative new products moving toward the marketplace. My focus is to make Iridex a leading provider of products for the treatment of glaucoma and retinal diseases, such as proliferative diabetic retinopathy, diabetic macular edema, and age-related macular degeneration.”

For more articles in this issue of Ophthalmology Times eReport, click here.